This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
4 Toxic Stocks That You Need to be Wary of & Dump Right Now
by Rimmi Singhi
If you own toxic stocks for a long period of time, you are sure to see huge erosion in your wealth. Figuring out such stocks and selling them at the right time is the key to successful investing.
CHRS or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CHRS vs. ILMN: Which Stock Is the Better Value Option?
Illumina (ILMN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is upbeat about its third-quarter sequencing consumable revenue growth.
Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
7 Diagnostic and Genomic Stocks Storming Into October
by Kevin Cook
COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.
Stock Market News for Sep 25, 2020
by Zacks Equity Research
Benchmarks closed in the positive territory on Thursday as tech stocks recovered some of the recent losses along with reports of a new stimulus bill in the making by House Democrats.
ANIK vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ANIK vs. ILMN: Which Stock Is the Better Value Option?
Company News for Sep 22, 2020
by Zacks Equity Research
Companies in the news are: MSFT, ROKU, NKLA, ILMN
Illumina-CDGN Partner to Create Coronavirus Tracking System
by Zacks Equity Research
Illumina (ILMN) partners with Australia's CDGN to track the national transmission of the virus causing COVID-19.
Zacks.com featured highlights include: ILMN, PFSW, CCJ and BMRN
by Zacks Equity Research
Zacks.com featured highlights include: ILMN, PFSW, CCJ and BMRN
These 4 Stocks Could Be Toxic for Your Portfolio
by Rimmi Singhi
Toxic stocks are sure to result in loss for investors over time. Figuring out such stocks on a consistent basis and discarding them at the right time is the key to successful investing.
Why Is Illumina (ILMN) Down 14.3% Since Last Earnings Report?
by Zacks Equity Research
Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Crocs, Illumina, Microsoft, Walmart and Oracle highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Crocs, Illumina, Microsoft, Walmart and Oracle highlighted as Zacks Bull and Bear of the Day
Bear of the Day: Illumina (ILMN)
by Madeleine Johnson
The coronavirus pandemic has dampened this medical stock's earnings and outlook.
LGND vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
4 Toxic Stocks to Discard From Your Portfolio Right Now
by Rimmi Singhi
If you own a toxic stock for long, you are likely to see a big loss in your wealth. Discarding them at the right time is the key to shield your portfolio from big losses.
Company News for Aug 10, 2020
by Zacks Equity Research
Companies In The News Are: ILMN, TTD, EOG, TMUS.
LGND vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
Illumina (ILMN) Q2 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits dismal performance in the second quarter of 2020 due to pandemic-led business disruptions.
Illumina (ILMN) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of -13.89% and -6.76%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Illumina (ILMN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is upbeat about its second-quarter sequencing consumable revenue growth.
BMY vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BMY vs. ILMN: Which Stock Is the Better Value Option?
GILD vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GILD vs. ILMN: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to Illumina Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN) backed by its focus on partnerships and robust demand for its products.